Real-world perspectives
Can You Trust Your Real-World Data?
In my last blog post, I talked about the three key imperatives that the industry faces in realizing the full potential of real-world evidenc…
Read
A Real World Dialogue with Dr. Leroy Hood of Institute of Systems Biology
Inaugural Real World Dialogue kicked off with industry heavyweight Dr. Leroy (Lee) Hood sharing his perspective on how real-world evidence will evolve over the years and its potential to end suffering from cancer and other health challenges.
ReadThe Innovation Engine That Could: Why It is Important to Carve Out Time to Innovate
Syapse made its presence known in the precision medicine and real-world evidence space over a decade ago. In this time, the use and understa…
ReadUnlocking the Potential of Real-World Evidence to Improve Cancer Care
Three essential challenges we must overcome in order to leverage real-world evidence to impact patient care, and how the ongoing pandemic will continue to shape our approaches to surmounting these challenges.
ReadThe FDA’s Recent Guidance on Diversifying Clinical Trials Can Revolutionize Cancer Care for Underrepresented Minorities
Clinical research serves to grow our understanding of how to best diagnose and treat cancer. For diseases such as testicular cancer and pe…
ReadReflecting on the Promise of Real-World Data, a Fireside Chat with the FDA
Please fill out the form below to view the recording. Syapse hosted its 3rd annual Precision Medicine Council to convene healthcare leade…
ReadFor People with Cancer — Further Evidence of Worse Outcomes Due to COVID-19
“Delays in screenings, diagnosis and treatment because of the coronavirus pandemic are likely to result in thousands of “excess” deaths from the disease in coming years.” Ned Sharpless, M.D., director of the National Cancer Institute
ReadJonathan Hirsch, President of Syapse, to participate in a discussion panel at the AACR Virtual Annual Meeting II
Monday, June 22, 2020, 4:40 PM - ET.
ReadQi Liu, PhD, of the U.S. Food and Drug Administration, discusses the findings from our collaborative research
Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer wh…
ReadSyapse, FDA, and Advocate Aurora Health to Present Safety Research at AACR Plenary Session
Over the course of my career, I have worked to advance the development of novel cancer therapeutics through classic phase I, II, and III cli…
ReadPrecision Medicine Goes Mainstream at Leading Health Systems
Precision medicine (or personalized medicine) has been a buzzword in the healthcare industry for many years. Depending on the audience, its…
ReadSyapse Expands Security Posture with HITRUST Certification
Patient data collected from electronic health records, molecular testing and patient reported outcomes is powering many of the most exciting…
ReadSeoul National University Hospital and Syapse Expand Collaboration to Increase Access to Precision Medicine in South Korea
This week, I had the privilege of joining our partners at Seoul National University Hospital (SNUH) to recognize our collaboration in servic…
ReadImproving Cancer Care with the Syapse Precision Medicine Council
When I first arrived at Syapse, I was impressed to hear that the company participated in the 2016 White House Cancer Moonshot Summit. Back t…
ReadExpanding Data Sharing is Imperative to Expanding Access to Quality Cancer Care
It’s common to hear that cancer care is in the midst of historic change. It is true: in 50 years, when books are written about the progress…
ReadSeoul National University Hospital Launches Syapse Platform, Hosts Symposium
A little over a week ago, we celebrated the first launch of our precision medicine platform outside of the U.S. at Seoul National University…
ReadWhy We Formed the Syapse Precision Medicine Council
When I started at Syapse earlier this year, I was impressed by the strategy to accelerate partnerships across the healthcare ecosystem and d…
ReadSyapse Named One of Fast Company’s World’s Most Innovative Companies
We are proud to announce that Syapse has been named a 2018 World’s Most Innovative Company by Fast Company. We are one of a select few compa…
ReadUniting the Precision Medicine Ecosystem to Improve Care for Cancer Patients
For almost nine months, I have been proud to lead Syapse in our mission to deliver the best care for every cancer patient through precision…
ReadNew Survey: Precision Medicine is Rapidly Becoming a Top Priority for Leading Health Systems
Health systems want to deliver the most innovative, effective cancer care to their patients and more and more of them are realizing the potential of precision medicine.
ReadWhy We Need More Data Sharing in Cancer Care
The Washington Post published a story this weekend that sums up why I am so excited about the future of precision medicine. The article…
ReadThree Challenges Precision Medicine Has to Overcome
Thirteen years ago, my father sat me down for the hardest conversation of my life. He told me that he had been diagnosed with Stage 4 colon…
ReadA Statement from Syapse in Support of the 21st Century Cures Act
Syapse is excited and encouraged by the passage of the 21st Century Cures Act. The continued funding of the Cancer Moonshot and Precision Me…
ReadJonathan Hirsch Featured in VP Biden's Cancer Moonshot Video
Watch Vice President Joe Biden and Cancer Moonshot participants discuss the need for fundamental changes in the fight to end cancer. Jonatha…
ReadPMWC16 Panel: Clinical Implementation of Precision Medicine Programs
Want to understand how healthcare systems and payers are approaching precision medicine? Watch this video of Syapse Founder & President Jona…
ReadAWS Interview with Jason Gillman of Intermountain Precision Genomics
Learn from Jason Gillman and Jonathan Hirsch about how Intermountain leveraged Syapse, running on Amazon Web Services, to address the e…
ReadOliver Wyman Executive Conversation with Jonathan Hirsch
Jonathan Hirsch recently teamed up with Oliver Wyman Associate Terrance Wallace to discuss the use of precision medicine to revolutionize cl…
ReadImproving Accrual Rates with the Syapse Clinical Trials Matching Feature
According to the American Cancer Society, “Fewer than 5% of adults (less than 1 in 20) with cancer will take part in a clinical trial&h…
ReadGuideWell Interview with Jonathan Hirsch at Oliver Wyman
On October 13th, Jonathan Hirsch sat with GuideWell’s Kate Warnock at the 2015 Oliver Wyman Health Innovation Summit to discuss what is need…
ReadA Blueprint for Precision Medicine at Swedish Cancer Institute
As community health systems adopt precision medicine, providing a roadmap for implementation of a precision medicine program is a key part o…
ReadSyapse Joins International Leaders in Precision Medicine in Support of the Manhattan Institute's Project FDA
Syapse is proud to join leaders in the fields of precision medicine and public policy in support of the Manhattan Institute’s Project F…
ReadUCSF Partners with Syapse to Tackle Infectious Disease
We’re excited to be working with UCSF to extend the reach of precision medicine beyond cancer and into pathogen detection. Each ye…
ReadHow Syapse Puts the "Action" into Clinically Actionable Genomic Data
A leading cancer center estimates that “currently only 10% to 20% of patients with actionable mutations actually end up on a [targeted] drug…
ReadVideo of PMWC 2015 panel, "Genomic Profiling Moving Into Routine Clinical Care" available!
Earlier this year at the Personalized Medicine World Conference 2015 in Silicon Valley, Founder & President Jonathan Hirsch moderated the pa…
ReadAWS re:Invent video and slides now available!
In case you weren’t able to see it in person, Jonathan Hirsch’s recent talk with Kristen McCaleb of UCSF and Nate Slater of AWS at AWS…
ReadSyapse Named as Innovation Showcase Finalist at HealthBeat 2014
We were very proud to be named as a finalist for HealthBeat 2014’s Innovation Showcase. In VentureBeat’s words: “Spurre…
ReadSyapse at Health 2.0
See Jonathan Hirsch’s short but sweet demo at this year’s Health 2.0 Conference. (Note: Jonathan Hirsch is the Founder & President of…
Read